Last reviewed 2026-04-23 · How we verify

Antibody Drug Conjugate Chemotherapeutic

Antibody Drug Conjugate Chemotherapeutic is a Antibody drug conjugate chemotherapeutic Biologic drug developed by Pfizer. It is currently in Phase 2 development for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic triple-negative breast cancer. Also known as: Gemtuzumab ozogamicin.

Antibody drug conjugates target specific cancer cells by binding to a protein on the cell surface and delivering a toxic payload.

Antibody drug conjugates target specific cancer cells by binding to a protein on the cell surface and delivering a toxic payload. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic triple-negative breast cancer.

At a glance

Mechanism of action

This mechanism involves the use of monoclonal antibodies that are engineered to bind to a specific protein on the surface of cancer cells. Once bound, the antibody is internalized by the cell, releasing a toxic payload that kills the cell.

Approved indications

• Metastatic non-small cell lung cancer, PD-L1 positive
• Metastatic triple-negative breast cancer

Common side effects

• Neutropenia
• Thrombocytopenia
• Fatigue

Key clinical trials

• A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors (PHASE1, PHASE2)
• Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PHASE1, PHASE2)
• Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer (PHASE2)
• A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression (PHASE3)
• Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer (PHASE1)
• A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer (PHASE3)
• Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Antibody Drug Conjugate Chemotherapeutic CI brief — competitive landscape report
• Antibody Drug Conjugate Chemotherapeutic updates RSS · CI watch RSS
• Pfizer portfolio CI

Frequently asked questions about Antibody Drug Conjugate Chemotherapeutic

Related

• Drug class: All Antibody drug conjugate chemotherapeutic drugs
• Manufacturer: Pfizer — full pipeline
• Therapeutic area: All drugs in Oncology
• Indication: Drugs for Metastatic non-small cell lung cancer, PD-L1 positive
• Indication: Drugs for Metastatic triple-negative breast cancer
• Also known as: Gemtuzumab ozogamicin
• Compare: Antibody Drug Conjugate Chemotherapeutic vs similar drugs
• Pricing: Antibody Drug Conjugate Chemotherapeutic cost, discount & access